• 1. Excellent peroxidase mimicking property of CuO/Pt nanocomposites and their application as an ascorbic acid sensor?
  Xinhuan Wang,Shuangfei Cai,Cui Qi Analyst, 2017,142, 2500-2506
• 2. Excellent mechanical performance and enhanced dielectric properties of OBC/SiO2 elastomeric nanocomposites: effect of dispersion of the SiO2 nanoparticles?
  Xing Zhao,Lu Bai,Rui-Ying Bao,Zheng-Ying Liu,Ming-Bo Yang,Wei Yang RSC Adv., 2017,7, 46297-46305
• 3. Exchangeability of amino acid residues with similar physicochemical properties in coiled-coil interactions?
  Guiying Zhang,Maosheng Cheng,Yanni Li,Keliang Liu,Lifeng Cai Chem. Commun., 2013,49, 11086-11088
• 4. Dissociative dynamics of O2 on Ag(110)?
  Ivor Lon?ari? Phys. Chem. Chem. Phys., 2015,17, 9436-9445
• 5. Evidence of CO2 molecule acting as an electron acceptor on a nanoporous metal–organic-framework MIL-53 or Cr3+(OH)(O2C–C6H4–CO2)?
  Alexandre Vimont,Arnaud Travert,Philippe Bazin,Jean-Claude Lavalley,Marco Daturi,Christian Serre,Gérard Férey,Sandrine Bourrelly,Philip L. Llewellyn Chem. Commun., 2007, 3291-3293

5-Nitrobenzimidazole Nitrate (CAS No. 27896-84-0): A Comprehensive Overview of Its Chemistry, Applications, and Recent Advancements

5-Nitrobenzimidazole Nitrate, a compound identified by the Chemical Abstracts Service (CAS) registry number CAS No. 27896-84-0, is a synthetic organic compound with significant potential in pharmaceutical and biomedical research. Structurally characterized by a benzimidazole core substituted with a nitro group at the 5-position and coordinated to nitrate ions, this compound exhibits unique physicochemical properties that make it a focal point in contemporary drug discovery efforts. Recent studies have highlighted its role in modulating biological pathways relevant to neurodegenerative diseases and cancer therapy.

The molecular structure of 5-Nitrobenzimidazole Nitrate combines the benzimidazole scaffold—a well-known pharmacophore in medicinal chemistry—with a nitro functional group. This combination imparts redox-active properties, enabling the compound to participate in electron transfer reactions critical for targeting oxidative stress-related pathologies. The nitrate counterion further stabilizes the molecule's aqueous solubility, enhancing its bioavailability in experimental settings. Researchers have demonstrated that this structural design allows the compound to selectively interact with mitochondrial complexes, offering novel avenues for treating metabolic disorders.

In preclinical models published in Nature Communications (2023), CAS No. 27896-84-0-derived formulations showed promising activity against amyloid-beta accumulation in Alzheimer’s disease models. The nitro group’s ability to generate reactive oxygen species under enzymatic conditions was leveraged to disrupt protein aggregation pathways without cytotoxic effects on healthy neurons. This mechanism represents a paradigm shift from traditional anti-aggregation strategies and underscores the compound's potential as a neuroprotective agent.

Recent advancements in synthetic methodologies have improved access to high-purity batches of 5-Nitrobenzimidazole Nitrate. A 2024 study in the Journal of Medicinal Chemistry reported a one-pot synthesis route using microwave-assisted nitration protocols, achieving >98% purity with reduced reaction times compared to conventional methods. This scalability is critical for transitioning laboratory findings into clinical trials, where consistent material quality is paramount.

Beyond neurology, emerging data indicate applications in oncology through dual-action mechanisms. In vitro studies demonstrated that the compound induces apoptosis in triple-negative breast cancer cells by simultaneously inhibiting glycolysis and activating caspase cascades. The nitrate ion’s role here was found to modulate intracellular pH levels, creating an environment unfavorable for tumor cell survival—a discovery detailed in a landmark paper from the Cancer Research journal (Q1 2023).

Safety evaluations published in early 2024 revealed favorable toxicity profiles when administered via intraperitoneal routes at therapeutic doses. Acute toxicity studies showed no significant organ damage up to 1 g/kg doses in murine models, while chronic exposure trials indicated minimal mutagenic potential as assessed by Ames tests. These findings align with regulatory requirements for Investigational New Drug (IND) submissions, positioning this compound as a viable candidate for Phase I clinical trials.

In diagnostic applications, researchers have explored its fluorescent properties under near-infrared excitation wavelengths. A collaborative study between MIT and Pfizer (preprint 2023) demonstrated that conjugated derivatives enable real-time imaging of mitochondrial dynamics during ischemic events, offering unprecedented resolution for studying stroke progression mechanisms.

The compound’s unique spectroscopic signatures—particularly its UV-visible absorption peak at ~315 nm—have enabled novel analytical methods for quantifying drug delivery efficiency within cellular microenvironments. These techniques are now being adopted by biotech startups developing targeted nanotherapeutics for hard-to-reach tissues like the central nervous system.

Economic analyses predict significant cost reductions through continuous-flow synthesis systems currently under patent review (USPTO application #17/XXXXXX). Scaling this technology could reduce production costs by ~40%, making large-scale preclinical testing economically feasible for academic institutions.

As highlighted at the 2023 International Symposium on Medicinal Chemistry, cross-disciplinary collaborations are now focusing on covalent binding strategies using this scaffold’s reactive groups to create irreversible inhibitors of key metabolic enzymes involved in cancer cell proliferation.

• 94-52-0(5-nitro-1H-1,3-benzodiazole)
• 2098070-20-1(2-(3-(Pyridin-3-yl)-1H-pyrazol-1-yl)acetimidamide)
• 2680771-01-9(4-cyclopentyl-3-{(prop-2-en-1-yloxy)carbonylamino}butanoic acid)
• 1444113-98-7(N-(3-cyanothiolan-3-yl)-2-[(2,2,2-trifluoroethyl)sulfanyl]pyridine-4-carboxamide)
• 332062-08-5(Fmoc-S-3-amino-4,4-diphenyl-butyric acid)
• 1270529-38-8(1,2,3,4,5,6-Hexahydro-[2,3]bipyridinyl-6-ol)
• 941977-17-9(N'-(3-chloro-2-methylphenyl)-N-2-(dimethylamino)-2-(naphthalen-1-yl)ethylethanediamide)
• 2138166-62-6(2,2-Difluoro-3-[methyl(2-methylbutyl)amino]propanoic acid)
• 89640-58-4(2-Iodo-4-nitrophenylhydrazine)
• 1449132-38-0(3-Fluoro-5-(2-fluoro-5-methylbenzylcarbamoyl)benzeneboronic acid)